47 related articles for article (PubMed ID: 2934950)
21. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
Giclas PC
J Immunol; 1982 Jul; 129(1):168-72. PubMed ID: 6979566
[TBL] [Abstract][Full Text] [Related]
22. In vitro effects of organic solvents on immunity indicators in serum.
Stefanovic J; Starsia Z; Murgasová I; Absolonová O
J Hyg Epidemiol Microbiol Immunol; 1987; 31(1):1-7. PubMed ID: 3571967
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of complement activation by a secreted Staphylococcus aureus protein.
Lee LY; Höök M; Haviland D; Wetsel RA; Yonter EO; Syribeys P; Vernachio J; Brown EL
J Infect Dis; 2004 Aug; 190(3):571-9. PubMed ID: 15243934
[TBL] [Abstract][Full Text] [Related]
24. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
25. Biologically active peptides derived from the fifth component of complement.
Goldstein IM; Perez HD
Prog Hemost Thromb; 1980; 5():41-79. PubMed ID: 6999532
[No Abstract] [Full Text] [Related]
26. Antibodies directed against O-acetylated sialoglycoconjugates accelerate complement activation in Leishmania donovani promastigotes.
Bandyopadhyay S; Chatterjee M; Das T; Bandyopadhyay S; Sundar S; Mandal C
J Infect Dis; 2004 Dec; 190(11):2010-9. PubMed ID: 15529267
[TBL] [Abstract][Full Text] [Related]
27. Antibody-independent activation of C1, the first component of complement, by cardiolipin.
Kovacsovics T; Tschopp J; Kress A; Isliker H
J Immunol; 1985 Oct; 135(4):2695-700. PubMed ID: 4031497
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin-independent utilization of the classical complement pathway in opsonophagocytosis of Escherichia coli by human peripheral leukocytes.
Leist-Welsh P; Bjornson AB
J Immunol; 1982 Jun; 128(6):2643-51. PubMed ID: 6210733
[No Abstract] [Full Text] [Related]
29. Role of complement activation in cell adhesion to polymer blood contact surfaces.
Herzlinger GA; Cumming RD
Trans Am Soc Artif Intern Organs; 1980; 26():165-71. PubMed ID: 7245476
[No Abstract] [Full Text] [Related]
30. Effect of intramammary infusion of beta-1,3-glucan or interleukin-2 on leukocyte subpopulations in mammary glands of sheep.
Waller KP; Colditz IG
Am J Vet Res; 1999 Jun; 60(6):703-7. PubMed ID: 10376896
[TBL] [Abstract][Full Text] [Related]
31. The leukokinetic changes and complement activation associated with filtration leukapheresis.
Nusbacher J; Rosenfeld SI; Leddy JP; Klemperer MR; MacPherson JL
Exp Hematol; 1979; 7(4 Suppl):24-30. PubMed ID: 400706
[No Abstract] [Full Text] [Related]
32. [Alternative complement activation pathway. Its mechanism, importance and quantitative determination].
Gancevici GG; Popescu C
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1984; 29(3):209-21. PubMed ID: 6390651
[No Abstract] [Full Text] [Related]
33. Influence of a bagasse glucan (B0) on leukocyte aggregation and accumulation.
Li XY; Damerau B; Vogt W
Zhongguo Yao Li Xue Bao; 1985 Jun; 6(2):137-40. PubMed ID: 2934950
[No Abstract] [Full Text] [Related]
34. Effects of particulate beta-1,3 glucan on human, rat, and guinea pig complement activity.
Glovsky MM; Cortes-Haendchen L; Ghekiere L; Alenty A; Williams DL; Di Luzio R
J Reticuloendothel Soc; 1983 May; 33(5):401-13. PubMed ID: 6601707
[TBL] [Abstract][Full Text] [Related]
35. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor.
Czop JK; Austen KF
J Immunol; 1985 Nov; 135(5):3388-93. PubMed ID: 4045195
[TBL] [Abstract][Full Text] [Related]
36. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
